Table 1.
Descriptive statistics of the study sample.
| Unvaccinated (n = 1204) | Vaccinated (n = 1147) | |
|---|---|---|
| Age (mean, SD) | 44.0 (12.5) | 42.9 (12.6) |
| Male sex | 430 (35.7%) | 390 (34%) |
| Disease-modifying treatment | ||
| None | 168 (14.0%) | 120 (10.5%) |
| Glatiramer acetate | 151 (12.5%) | 124 (10.8%) |
| Interferons | 237 (19.7%) | 205 (17.9%) |
| Teriflunomide | 86 (7.1%) | 78 (6.8%) |
| Dimethyl fumarate | 248 (20.6%) | 238 (20.7%) |
| Fingolimod | 202 (16.8%) | 259 (22.6%) |
| Cladribine | 34 (2.8%) | 43 (3.7%) |
| Azathioprine | 14 (1.2%) | 11 (1.0%) |
| Alemtuzumab | 2 (0.2%) | 0 (0.0%) |
| Natalizumab | 36 (3.0%) | 26 (2.3%) |
| Ocrelizumab | 21 (1.7%) | 35 (3.1%) |
| Rituximab | 5 (0.4%) | 8 (0.7%) |
| Number of comorbidities | ||
| 0 | 913 (75.8%) | 872 (76.0%) |
| 1 | 174 (14.5%) | 173 (15.1%) |
| 2 | 65 (5.4%) | 57 (5.0%) |
| 3 | 36 (3.0%) | 38 (3.3%) |
| 4+ | 16 (1.3%) | 7 (0.6%) |